Structure-activity relationship studies on a novel family of specific HIV-1 reverse transcriptase inhibitors

Antiviral Chemistry and Chemotherapy

Volumn 14, Issue 5, 2003, Pages 249-262

  Bonache, María Cruz ^a   Chamorro, Cristina ^a   Lobatón, Esther ^a   De Clercq, Erik ^b   Balzarini, Jan ^b   Velázquez, Sonsoles ^a   Camarasa, María José ^a   San Félix, Ana ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

AIDS; HIV; N 3 carboxymethyl TBDMS substituted nucleosides; NNRTI; Non nucleoside reverse transcriptase inhibitors

Indexed keywords

1 [2',5' BIS O (TERT BUTYLDIMETHYLSILYL) BETA DEXTRO RIBOFURANOSYL] 2 N [(CARBOXY)METHYL]THYMINE; 2',5' BIS O (TERT BUTYLDIMETHYLSILYL) 1 N [(CARBOXY)METHYL]INOSINE; 3',5' BIS O (TERT BUTYLDIMETHYLSILYL) 1 N [(CARBOXY)METHYL]INOSINE; DIDANOSINE; HYPOXANTHINE DERIVATIVE; NEW DRUG; NUCLEOSIDE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFICACY; DRUG STRUCTURE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION;

EID: 0345098561     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020301400504     Document Type: Article

References (40)

1. Alvarez R, Jimeno ML, Pérez-Pérez MJ, De Clercq E, Balzarini J & Camarasa MJ (1997) Synthesis and anti-HIV-1 activity of novel 3′-spiro nucleosides analogues of TSAO-T. Antiviral Chemistry & Chemotherapy 8: 507-517.
2. Arnold E, Das K, Ding J, Yadav PN, Hsiou Y, Boyer PL, Hughes SH (1996) Targeting HIV reverse transcriptase for anti-AIDS drug design: structural and biological considerations for chemotherapeutic strategies. Drug Design & Discovery 13: 29-47
3. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, Katlama C, Debre, P & Leibowitch J (1997) Positive effects of combined antiretroviral therapy on CD4 (+)T cell homeostasis and function in advanced HIV disease. Science 277: 112-116.
4. Balzarini J, Kleim JP, Riess G, Camarasa MJ, De Clercq E & Karlsson A (1994) Sensitivity of (Glu138Lys) mutated human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) to HIV-1 specific RT inhibitors. Biochemical & Biophysical Research Communications 201: 1305-1312.
5. Balzaríni J, Pérez-Pérez MJ, San-Félix A, Schols D, Perno CF, Vandamme AM, Camarasa MJ & De Clercq E (1992a) 2′,5′-Bis-O-(tert-butyldimethylsilyl)-3′-spiro-5″ -(4″-amino-1″,2″-oxathiole-2″,2″-dioxide) pyrimidine (TSAO) nucleoside analogues: highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase. Proceedings of the National Academy of Sciences, USA 89: 4392-4396.
6. Balzarini J, Pérez-Pérez MJ, San-Félix A, Camarasa MJ, Bathurst IC, Barr PJ & De Clercq E (1992b) Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2′,5′ -Bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl]-3′-spiro-5″ -(4″-amino-1″,2″-oxathiole-2″,2″-dioxide) thymine (TSAO-T). Journal of Biological Chemistry 267: 11831-11838.
7. Belmonte L, Bare P, De Bracco MM & Ruibal-Ares BH (2003) Reservoirs of HIV replication after successful combined antiretroviral therapy. Current Medicinal Chemistry 10: 303-312.
8. Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski S & Helm EB (1997) Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 11: 1731-1738.
9. Bussolari JC & Panzica RP (1999) Synthesis and anti-HIV-evaluation of 2′,3′-dideoxyimidazo- and v-triazolo[4,5-d]pyridazine nucleosides. Bioorganic & Medicinal Chemistry 7: 2373-2379.
10. Calvo-Mateo A, Camarasa MJ, Díaz-Ortíz A, De las Heras FG & Alemany A (1988) Synthesis of 3′-C-cyano-3′ -deoxypentofuranosylthymine nucleosides. Tetrahedron 44: 4895-4903.
11. Camarasa MJ, Pérez-Pérez MJ, San-Félix A, Balzarini J & De Clercq E (1992) 3′-Spiro nucleosides, a new class of specific human immunodeficiency virus type 1 inhibitors: synthesis and antiviral activity of [2′,5′-Bis-O-(tert-butyldimethylsilyl) -β-D-xylo-and -ribofuranose]-3″-spiro-5″-(4″ -amino-1″,2″-oxathiole-2″,2″-dioxide) (TSAO)pyrimidine nucleosides. Journal of Medicinal Chemistry 35: 2721-2727.
12. Camarasa MJ, San-Félix A, Pérez-Pérez MJ, Velázquez S, Alvarez R, Chamorro C, Jimeno ML, Pérez C, Gago F, De Clercq E & Balzarini J (2000) HIV-1 Specific reverse transcriptase inhibitors: why are TSAO-nucleosides so unique?. Journal of Carbohydrate Chemistry 19: 451-469.
13. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ & Cooper DA (1998) A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12: F51-F58.
14. Cushley RJ, Watanabe KA & Fox JJ (1967) Nucleosides XXXVIII. Proton magnetic resonance studies of acetylated nucleosides. Journal of the American Chemical Society 89: 394-400.
15. Chamorro C, Lobatón E, Bonache MC, De Clercq E, Balzarini J, Velázquez S, San-Félix A & Camarasa MJ (2001) Identification of a novel family of nucleosides that specifically inhibit HIV-1 reverse transcriptase. Biorganic & Medicinal Chemistry Letters 11: 3085-3088.
16. Chu CK, Bhadti VS, Doboszewski B, Gu ZP, Kosugi Y, Pullaiah K C & Van Roey P (1989) General synthesis of 2′,3′-dideoxynucleosides and 2′-3′-didehydro-2′,3′-dideoxynucleosides. Journal of Organic Chemistry 54: 2217-2225.
17. Chu C, Warren Beach J, Ullas V & Kosugi Y (1988) An efficient total synthesis of 3′-azido-3′-deoxythymidine (AZT) and 3′-azido-2′,3′-dideoxyuridine (AZDDU, CS-87) from D-mannitol. Tetrahedron Letters 29: 5349-5352.
18. Daudon M, Estepa L, Viard JP, Joly D & Jungers P (1997) Urinary stones in HIV-1-positive patients treated with indinavir. Lancet 349:1294-1295.
19. De Clercq E (1998) The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Research 38: 153-179.
20. De Clercq E (1995) Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. Journal of Medicinal Chemistry 38: 2491-2517.
21. De Clercq E (1997) In search of a selective antiviral chemotherapy. Clinical & Microbiology Reviews 10: 674-693.
22. Duncia JV, Chiu AT, Carini DJ, Gregory GB, Johnson AL, Price WA, Wells GJ, Wong PC, Calabrese JC & Timmermans PBMWM (1990) The discovery of potent nonpeptide angiotensin II receptor antagonists: a new class of potent antihypertensives. Journal of Medicinal Chemistry 33: 1312-1329.
23. Herr RJ (2002) 5-Substituted-1H-tetrazoles as carboxylic isosteres: medicinal chemistry and synthetic methods. Bioorganic & Medicinal Chemistry 10: 3379-3393.
24. Jonckheere H, Anné J & De Clercq E (2000) The HIV-1 reverse transcription (RT) process as target for RT inhibitors. Medicinal Research Reviews 20: 129-154.
25. Jonckheere H, Taymans JM, Balzarini J, Velázquez S, Camarasa MJ, Desmyter J, De Clercq E & Anné J (1994) Resistance of HIV-1 reverse transcriptase against [2′,5′ -Bis-O-(tert-butyldimethylsilyl)-3′-spiro-5″-(4″ -amino-1″,2″-oxathiole-2″,2″-dioxide)] (TSAO) derivatives is determined by the mutation Glu138Lys on the p51 subunit. Journal of Biological Chemistry 269: 25255-25258.
26. Katz RA & Skalka AM (1994) The retroviral enzymes. Annual Review of Biochemistry 63: 133-173.
27. Kaufmann D, Pantaleo G, Sudre P & Telenti A (1998) CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study. Lancet 351: 723-724.
28. Kim SH, Yoo S-M, Park IS & Kim YH (2000) A new inosine disaccharide from the crustacean ligia exotica: isolation and structure elucidation by total synthesis. Journal of Natural Products 63:1188-1191.
29. Ogilvie KK, Beaucage SL, Shifman AL, Theriault NY & Sadana K (1978) The synthesis of oligoribonucleotides. II. The use of silyl protecting groups in nucleoside and nucleotide chemistry. VII. Canadian Journal of Chemistry 56: 2768-2780.
30. Otera J, Dan-oh N & Nozaki H (1991) novel template effects of distannoxane catalysts in highly efficient transesterification and esterification Journal of Organic Chemistry 56: 5307-5311.
31. Patani GA & LaVoie EJ (1996) Bioisosterism: a rational approach in drug design. Chemical Reviews 96: 3147-3176.
32. Pedersen OS, Pedersen EB (1999) Non-nucleoside reverse transcriptase inhibitors: the NNRT1 boom. Antiviral Chemistry and Chemotherapy 10: 285-314.
33. Pérez-Pérez MJ, San-Félix A, Balzarini J, De Clercq E & Camarasa MJ (1992) TSAO-analogues. Stereospecific synthesis and anti-HIV-1 activity of 1-[2′,5′ -Bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl]-3′-spiro-5″ -(4″-amino-1″,2″-oxathiole-2″,2″-dioxide) pyrimidine and pyrimidine-modified nucleosides. Journal of Medicinal Chemistry 35: 2988-2995.
34. Perrin L & Telenti A (1998) HIV treatment failure: testing for HIV resistance in clinical practice. Science 280: 1871-1873.
35. Pontikis R, Dollé V, Guillaumel J, Dechaux E, Note R, Nguyen CH, Legraverend M, Bisagni E, Aubertin A-M, Grierson DS & Monneret C (2000) Synthesis and evaluation of 'AZT-HEPT', 'AZT-Pyridinone', and 'ddC-HEPT' conjugates as inhibitors of HIV Reverse Transcriptase. Journal of Medicinal Chemistry 43: 1927-1939.
36. Saag MS & Kilby JM (1997) HIV-1 and HAART: a time to cure, a time to kill. Nature Medicine 5: 609-611.
37. Schinazi RF (1993) Competitive inhibitors of human immunodeficiency virus reverse transcriptase. Perspective in Drug Discovery 1: 151-180.
38. Szemzö A, Szabolcs A, Sági J & Ötvös L (1980) Unnatural nucleosides and nucleotides. IV. Preparation of 5-alkyluridines and their 5′-mono-and triphosphates. Journal Carbohydrates, Nucleosides & Nucleotides 7: 365-379.
39. Valdez H (2002) Immune restoration after treatment of HIV-1 infection with highly active antiretroviral therapy (HAART). AIDS Reviews 4: 157-164.
40. 13C NMR spectral characteristics of 8-bromo-2′,3′ -dideoxyguanosine and 8-bromo-2′,3′-dideoxyinosine. Nucleosides & Nucleotides 15: 1077-1096.